PCM
CRL icon

Peregrine Capital Management’s Charles River Laboratories CRL Stock Holding History

Peregrine Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-89,129
Closed -$7.97M – 250
2017
Q1 		$7.97M Buy
+89,129
New +$7.57M 0.2% 215

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Peregrine Capital Management's CRL Position: Q2 2017 in Review

Peregrine Capital Management sold out of Charles River Laboratories (CRL) in Q2 2017, closing a stake of 89,129 shares — an estimated $7.97M sold.

Peregrine Capital Management first reported a position in CRL in Q1 2017 and held it in 1 quarter. The position peaked at $7.97M in Q1 2017. 302 funds tracked by Wall St. Rank hold CRL as of Q2 2017.

  • Peregrine Capital Management reported no remaining Charles River Laboratories position as of Q2 2017 after selling out during the quarter.
  • Peregrine Capital Management sold 89,129 Charles River Laboratories shares in Q2 2017, an estimated $7.97M.
  • Peregrine Capital Management first reported a position in Charles River Laboratories in Q1 2017 and held it in 1 quarter.
  • Peregrine Capital Management's Charles River Laboratories position peaked at $7.97M in Q1 2017.
  • 302 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2017.

Based on Peregrine Capital Management's 13F filing for Q2 2017, filed 19 Jul 2017.